N/A
N=3,504
Consumer Perceptions of Cannabidiol (CBD) Health Claims
Perceptions
Bottom Line
View on ClinicalTrials.gov: NCT06069713 ↗Enrolled (actual)
3,504
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Perceived Claim Scores — 2.96; 2.81; 2.71; 2.03 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CBD advertisements (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Perceived Claim Scores |
2.96; 2.81; 2.71; 2.03; 1.76; 1.64 | — |
| SECONDARY Perceived Product Safety Scores |
3.34; 3.11; 2.92 | — |
| SECONDARY Appeal Scores |
2.82; 2.42; 1.81 | — |
Summary
Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These types of claims may reduce perceptions of harm and increase perceived benefits of use. This study aims to evaluate how consumers perceive real-world CBD advertisements. To that end, we will implement an online survey and randomize adult participants (ages 18-65) to see various advertisements made about CBD to determine if they interpret advertisements as making health claims that are currently prohibited by the FDA.
Eligibility Criteria
Inclusion Criteria
- Age 18-65
- US Residents
- Satisfies one of the following categories:
- Current CBD users
- Ever CBD users
- Non-CBD users
- Members of the AmeriSpeak™ panel
Exclusion Criteria
- Non-English speakers
- Younger than 18 or older than 65
- Not US residents
- Not members of the AmeriSpeak™ panel
Data sourced from ClinicalTrials.gov (NCT06069713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.